HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 23, 17718-17727, June 9, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/23/17718    most recent M909946199v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gao, X.-D. Articles by Dean, N. Search for Related Content PubMed PubMed Citation Articles by Gao, X.-D. Articles by Dean, N. Social Bookmarking                      What's this?

Distinct Protein Domains of the Yeast Golgi GDP-mannose Transporter Mediate Oligomer Assembly and Export from the Endoplasmic Reticulum^*

Xiao-Dong Gao and Neta Dean

From the Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York, Stony Brook, New York 11794-5215

Received for publication, December 8, 1999, and in revised form, March 10, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The substrates for glycan synthesis in the lumen of the Golgi are nucleotide sugars that must be transported from the cytosol by specific membrane-bound transporters. The principal nucleotide sugar used for glycosylation in the Golgi of the yeast Saccharomyces cerevisiae is GDP-mannose, whose lumenal transport is mediated by the VRG4 gene product. As the sole provider of lumenal mannose, the Vrg4 protein functions as a key regulator of glycosylation in the yeast Golgi. We have undertaken a functional analysis of Vrg4p as a model for understanding nucleotide sugar transport in the Golgi. Here, we analyzed epitope-tagged alleles of VRG4. Gel filtration chromatography and co-immunoprecipitation experiments demonstrate that the Vrg4 protein forms homodimers with specificity and high affinity. Deletion analyses identified two regions essential for Vrg4p function. Mutant Vrg4 proteins lacking the predicted C-terminal membrane-spanning domain fail to assemble into oligomers (Abe, M., Hashimoto, H., and Yoda, K. (1999) FEBS Lett. 458, 309-312) and are unstable, while proteins lacking the N-terminal cytosolic tail are stable and multimerize efficiently, but are mislocalized to the endoplasmic reticulum (ER). Fusion of the N terminus of Vrg4p to related ER membrane proteins promote their transport to the Golgi, suggesting that sequences in the N terminus supply information for ER export. The dominant negative phenotype resulting from overexpression of truncated Vrg4-N proteins provides strong genetic evidence for homodimer formation in vivo. These studies are consistent with a model in which Vrg4p oligomerizes in the ER and is subsequently transported to the Golgi via a mechanism that involves positive sorting rather than passive default.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The Golgi complex serves as the intracellular site for the terminal carbohydrate modifications of proteins and lipids. These modifications are essential for life and play a variety of important biological roles, from protein folding to the regulation of cell surface properties. The substrates for the carbohydrate modification of both glycoproteins and glycolipids in the Golgi are nucleotide sugars, whose site of synthesis is the cytosol. These molecules must be transported into the Golgi lumen by membrane-bound nucleotide sugar transporters (NSTs)¹ to be utilized by the glycosyltransferases.

The current model for the transport of nucleotide sugars by the NSTs involves a one-for-one exchange reaction, in which the lumenal transport of a nucleotide sugar from the cytoplasm is coupled to the equimolar exit of the corresponding nucleotide monophosphate (2-4). The nucleotide monophosphate is generated through the action of the glycosyltransferases and nucleoside diphosphatases in the lumen of the Golgi. As a consequence of their role in substrate provision, the NSTs play an indispensable role in glycoconjugate synthesis, best evidenced by the severe phenotype of mutants with defects in Golgi transport of nucleotide sugars (for review, see Refs. 5 and 6).

Many NST activities have been reported, which differ from one another in their substrate specificity. The diversity of glycosylation reactions in the mammalian Golgi requires the transport of many different nucleotide sugars and a correspondingly large number of NSTs. In contrast, the vast majority of carbohydrate modifications in the yeast Golgi are restricted to mannose additions that utilize GDP-mannose as the nucleotide sugar substrate (7). In the yeast, Saccharomyces cerevisiae, lumenal GDP-mannose transport requires the VRG4 gene product (8). Mutations in this gene lead to a loss of nucleotide sugar transport in vitro and the underglycosylation of glycoproteins and glycosphingolipids in vivo. A deletion of the VRG4 gene is lethal, demonstrating that mannosylation in the Golgi is essential (9). Its strong homology to the Leishmania GDP-mannose transporter as well as to a large number of other NSTs (8, 10) argues that the Vrg4 protein functions as a transporter per say, rather than as a regulator of transport.

It is the concerted action of both the glycosyltransferases and the NSTs that ultimately dictate glycoconjugate synthesis. Although much is known about the glycosyltransferases, relatively little is known about the biochemical and molecular basis by which the NSTs transport nucleotide sugars from the cytosol into the Golgi. We have undertaken an analysis of the Vrg4 protein to gain a better understanding of NST function. Here data are presented that suggest this protein functions as a homodimer. In addition, deletion analysis of mutant proteins has enabled us to identify a region of the protein that is essential for its exit from the ER and proper Golgi localization but that, when mutated, does not interfere with protein stability or oligomerization. This N-terminal region is distinct from a C-terminal domain required for oligomerization (1) and protein stability. Like Vrg4 proteins lacking the cytosolic N-terminal domain, these Vrg4C proteins are also retained in the ER (1) but probably because they are misfolded and incompletely assembled. When present on a protein that resides in the ER, a sequence homologous to the N terminus of Vrg4p targets the heterologous protein to the Golgi, suggesting that sequences in the N terminus act as a positive ER export signal.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Yeast Strains and Media-- Standard yeast media and genetic techniques were used (11). Hygromycin B sensitivity was tested on yeast extract/peptone/adenine sulfate/dextrose plates (YPAD) supplemented with 50 µg/ml hygromycin B (Roche Molecular Biochemicals) as described previously (12). SEY6210 (MAT ura3-52 leu2-3, 112 his3-200 trp1-901 lys2-801 suc29) was used as the parental strain for the construction of XGY10 and XGY12, in which the chromosomal alleles of VRG4 or GDA1, respectively, are replaced with those that contain a C-terminal tobacco etch virus (TEV) protease cleavage site fused to a protein A tag (see below). XGY11 was constructed from W303a (MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3, 112 can1-100) and contains a replacement of the normal VRG4 locus with an allele in which VRG4 is tagged at the N terminus with a triple HA-TEV tag and is under the control of the GAL1 promoter. NDY5 (MAT ura3-52 leu2-211 vrg4-2) (9) was used for complementation analysis of the vrg4-2 allele. XGY13 is a derivative of RSY255 (MAT ura3-52 leu2-211) but contains an HA-tagged allele of VRG4 integrated at the ura3-52 locus, driven by the TPI promoter (8).

The chromosomal VRG4 and GDA1 alleles were tagged at the 3'-end with sequences encoding the TEV protease cleavage site followed by the protein A IgG binding domain, using PCR-mediated gene modification by homologous recombination (13-15). A fragment, encoding the TEV protease cleavage site (SENLYFQG) (16) followed by the protein A "Z" domains and the Schizosaccharomyces pombe HIS5 gene, was amplified from the plasmid pZZ-HIS5 (17) and targeted to the 3'-end of either the VRG4 or GDA1 gene. Similarly, the chromosomal VRG4 allele was tagged at the 5'-end with sequences encoding three copies of the HA epitope and the TEV protease cleavage site. A fragment was amplified by PCR from plasmid pFA6a-His3MX6-PGAL1-3HA (18), which contains the HIS5 marker and the GAL1 promoter followed by the HA tag. A TEV protease cleavage site was inserted at the junction between the first methionine of the VRG4 ORF and the HA tag by including DNA sequences encoding this cleavage site sequence directly in the reverse primer used in the PCR amplification.

Plasmids-- Plasmids used in this study are listed in Table I. Standard molecular biology techniques were used for all plasmid constructions (19).

To construct pRHL-myc₃, the VRG4 gene was cloned in-frame to sequences encoding three tandem copies of the myc epitope (EQKLISEEDL). A HindIII/NsiI fragment containing the VRG4 ORF lacking the stop codon was isolated by PCR and cloned into pSKP/X myc₃, a derivative of Bluescript SK (Stratagene). pSKP/X myc₃ carries a 172-base pair fragment encoding three tandem copies of the myc epitope, cloned between the PstI and XbaI sites of pBluescript SK. pSKVRG4-myc₃ encodes Vrg4p fused to three copies of the myc epitope at the C terminus. SKVRG4-myc₃ was used to generate pRHL-myc₃, which contains VRG4-myc₃, under the control of its own promoter, on an EcoRI/HindIII fragment in the CEN6/URA3 vector, pRS316 (20). This EcoRI/HindIII fragment from pRHL-myc₃ was cloned into YEplac181 (21) to generate YEplac181-RHL-myc₃ to allow expression in a 2µ/LEU2 vector and into YEp352 (22) to generate YEp352-RHL-myc₃ to allow expression in a 2µ/URA3 vector. Identical constructs, but containing the triple HA tag at the C terminus are pRHL-HA₃, YEplac181-RHL-HA₃, and YEp352 RHL-HA₃.

A series of plasmids containing vrg4 alleles with 5' deletions were constructed by PCR amplification using pSK-RHL HA₃ as the template plasmid (8). Each of the deletion constructs shares the same 3'-end, including sequences encoding the C-terminal triple HA-tag. KpnI/SmaI amplified fragments, amplified by PCR, containing deleted 5' termini of VRG4 were ligated into the KpnI/PvuII sites of pYEpGAP (23) to place them under the control of the glyceraldehyde-3-phosphate dehydrogenase (TDH3) promoter in a 2µ/URA3 yeast expression plasmid. An ATG sequence in YEpGAP encodes the initiating methionine in each these vrg4N alleles. 5' primers for these PCR reactions were designed to amplify from the codon encoding the 16th, 45th, or 79th amino acid of Vrg4p, respectively, to generate the series pYEpGAP15N-HA₃, pYEpGAP44N-HA₃, and pYEpGAP78N-HA₃. Similarly, an EcoRI/SmaI fragment containing the entire wild type VRG4-HA gene was amplified by PCR and ligated into the EcoRI/PvuII sites of YEp352GAP vector to create pYEpGAPVRG4-HA₃. An analogous series of plasmids, encoding Vrg4N proteins that were myc-tagged, was derived from the YEpGAPN plasmids described above by replacing the 3'-half of each VRG4 gene with a HpaI/SacI fragment from pRHL-myc3. Each of the BamHI/SacI fragments were inserted into Yeplac181. This series of plasmids encode Vrg4p with N-terminal deletions (15, 44, and 78) and a C-terminal myc epitope, whose expression is under the control of the TDH3 promoter in a 2µ/LEU2 plasmid.

To construct plasmids encoding C-terminal Vrg4p deletion mutants, we first made a vector (YEpGAP-N-myc₃) containing a fragment encoding three copies of the myc epitope, flanked by an EcoRI/KpnI site and containing an initiating ATG, in YEpGAP. KpnI/SmaI DNA fragments containing deleted 3' termini of VRG4 were amplified and ligated into the KpnI/PvuII sites of YEpGAP, in-frame and 3' to the myc₃ epitope. The 3' PCR primers were designed to delete the last 6, 13, or 34 amino acids of Vrg4p to generate YEpGAP6C-myc₃, YEpGAP13C-myc₃, and YEpGAP34C-myc₃. These plasmids encodeVrg4p C-terminal deletions with an N-terminal myc epitope, whose expression is under the control of the TDH3 promoter in a 2µ/URA3 plasmid.

An HA-tagged allele of the HVG1 gene was created in several steps. First, a fragment containing the HVG1 ORF, lacking the stop codon and flanked by a 5' HindIII and a 3' NsiI site was amplified by PCR from yeast genomic DNA and cloned into pSKP/X HA₃ (24) to generate pSKHVG1-HA₃. This plasmid encodes Hvg1p with the HA₃ epitope at the C terminus. A HindIII/NotI fragment from SKHVG1-HA₃ containing HA-tagged HVG1 was cloned into pRS316TPI (9) to generate pRS TPI-HVG1-HA₃. This places HA-tagged HVG1 under the control of the TPI promoter in a CEN6/URA3 yeast expression plasmid. YEpTPI-HVG1-HA₃ contains the SalI/SacI fragment from pRS TPI-HVG1-HA₃ in pYEp352.

To construct a plasmid that encodes Hvg1p with an N-terminal extension homologous to that of Vrg4p, site-directed mutagenesis was used to change the stop codon located 60 base pairs upstream the first ATG of the HVG1 ORF to an arginine codon normally found at amino acid 78 of the Vrg4 protein. A HindIII/NsiI fragment containing the entire HVG1 ORF as well as 275 base pairs of 5'-flanking sequences was isolated by PCR and cloned into pSKP/X HA₃ to place the HA₃ epitope at the 3'-end. This plasmid was used as template DNA for site-directed mutagenesis of HVG1, using the QuikChange^TM Site-Directed Mutagenesis kit (Stratagene). The mutagenic primers change the T of the stop codon (TGA) to a C to produce an arginine codon (CGA). This generated a 98-amino acid extension in the N terminus of HVG1 ORF to create pSK mHVG1-HA₃. A 1.13-kilobase pair HindIII/NotI fragment from pSK mHVG1-HA₃ was cloned into pRS316TPI to make pRSTPI-mHVG1-HA₃. This places the mutated HVG1 (mHVG1) under the control of the TPI promoter in a CEN6/URA3 yeast expression plasmid. Similar to YEpTPI-HVG1-HA₃, YEpTPI-mHVG1-HA₃ was also produced by cloning the SalI/SacI fragment from pRS TPI-mHVG1-HA₃ into YEp352.

A fragment containing the entire YPL244C ORF was isolated by PCR from yeast genomic DNA and cloned into pSKP/X HA₃ to place the HA₃ epitope at the 3'-end of Ypl244p. YEpGAPYpl244-HA₃ and YEpGAPYpl24441-HA₃ were constructed by cloning a KpnI/SmaI fragment (amplified by PCR) into YEpGAP. YEpGAP-V_N47Ypl24441-HA₃ was constructed by fusing a fragment encoding the N-terminal 47 amino acids of Vrg4p in-frame into the EcoRI/KpnI site of YEpGAPYpl24441-HA₃.

Preparation of Cell-free Lysates-- Exponentially growing yeast cells (A₆₀₀: 1-3) were harvested and converted to spheroplasts with lyticase, as described previously (25). Spheroplasts from 3-4 OD units of cells were resuspended in 400 µl of ice-cold lysis buffer (150 mM NaCl, 10 mM HEPES-KOH (pH 7.5), 5 mM MgCl₂, 1 mM PMSF) containing either 1% digitonin or 1% Triton X-100 to solubilize membrane proteins and centrifuged for 5 min at 4 °C at 14,000 × g to remove debris. These detergent extracts were used for both FPLC analysis and the co-immunoprecipitation assays described below.

For preparation of a membrane fraction, 50 A₆₀₀ units of cells were spheroplasted using lyticase (25). The spheroplasts were resuspended in 1 ml of cold lysis buffer (0.1 M sorbitol, 50 mM potassium acetate, 2 mM EDTA, 20 mM HEPES (pH 7.4), 1 mM dithiothreitol) containing a protease inhibitor mixture (1 mM PMSF, 1 µg/ml pepstatin, 50 µg/ml N-tosyl-L-lysine chloromethyl ketone, 100 µg/ml N-tosyl-L-phenylalanine chloromethyl ketone, and 100 µg/ml trypsin inhibitor). Lysis was carried out by Dounce homogenization (25 strokes) on ice, and unbroken cells were removed from the lysate by centrifugation for 5 min in a Microfuge. Membranes were isolated by centrifugation at 100,000 × g for 30 min in a Beckman Optima TL ultracentrifuge. The membrane pellet was resuspended in 150 µl of lysis buffer and used for protease protection assays (see below).

Co-immunoprecipitation, Western Immunoblotting, and Immunofluorescence-- The HA-tagged proteins were immunoprecipitated by incubating 400 µl of the detergent extract (described above) with 200 µl of a hybridoma cell culture supernatants containing the 12CA5 monoclonal anti-HA antibody and 25 µl of protein A-Sepharose (Amersham Pharmacia Biotech) at room temperature for 2 h. Immunoprecipitation of myc-tagged proteins was done identically, except we used culture supernatants containing the 9E10 monoclonal ant-myc antibody and the incubations were carried out at 4 °C overnight. The protein A-Sepharose beads and associated proteins were centrifuged and washed three times with the same lysis buffer (1% digitonin or 1% Triton X-100, 150 mM NaCl, 50 mM HEPES-KOH (pH 7.5), 5 mM MgCl₂, 1 mM PMSF). After resuspending in Laemmli's sample buffer and solubilizing at 45 °C for 3 min, immunoprecipitates were fractionated by 10% SDS-PAGE, transferred to Immobilon-polyvinylidene difluoride membranes (Millipore) and immunoblotted with anti-HA (Y-11) or anti-myc A-14 rabbit polyclonal antibodies (Santa Cruz Biotechnology). Secondary anti-rabbit antibodies conjugated to horseradish peroxidase (Amersham Pharmacia Biotech) were used at a 1:3000 dilution and detected by chemiluminescence (ECL, Amersham Pharmacia Biotech).

Whole cell protein extracts were prepared by trichloroacetic acid precipitation, as described previously (25). Proteins were separated by SDS-PAGE and detected by Western immunoblotting using anti-HA or anti-myc antibodies, as described previously (9). Culture supernatants, containing the monoclonal anti-HA antibody, 12CA5, or the monoclonal anti-myc antibody, 9E10, were used at a 1:10 dilution. Rabbit polyclonal IgG against the HA epitope (Y-11) and c-myc epitope (A-14) (Santa Cruz) were used at a 1:2000 dilution. Rabbit anti-mouse IgGs (Jackson ImmunoResearch Laboratories), used for the detection of the protein A tag, were used at a 1:5000 dilution. Secondary anti-rabbit or anti-mouse antibodies (Amersham Pharmacia Biotech), conjugated to horseradish peroxidase, were used at a 1:3000 dilution and were detected by chemiluminescence (ECL, Amersham Pharmacia Biotech).

Indirect immunofluorescence of yeast cells was performed as described previously (8). Samples were observed with a Zeiss Axioscop and photographed with a Sony DXC-9000 cooled CCD camera. Images were captured using NIH Image software, and all processing was done with Canvas (v.5) (Deneba).

TEV Protease Protection Assay-- Membrane fractions (10 µl) were prepared as described above and were mixed with 20 units of TEV protease (Life Technologies, Inc.) in a reaction containing (100 mM sorbitol, 50 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 1 mM dithiothreitol) in a final volume of 60 µl. In control reactions, Triton X-100 or zinc sulfate was added to a final concentration of 0.5% or 0.1 M, respectively. Reactions were incubated for 1 h at 30 °C. After diluting in SDS loading buffer to stop the reaction, proteins were separated by SDS-PAGE and further analyzed for proteolysis by immunoblotting with Rabbit anti-mouse IgGs for the detection of the protein A epitope or 12CA5 for the detection of the HA epitope, as described above.

Gel Filtration Chromatography-- 1% Triton X-100 or 1% digitonin cell-free extracts were prepared exactly as described above from yeast expressing the HA-tagged VRG4 allele (pRHL-HA₃). 200 µl of extract were fractionated over a gel filtration column (Superose 6 HR 10/30, Amersham Pharmacia Biotech) equilibrated with 150 mM NaCl, 50 mM HEPES-KOH (pH 7.5), 5 mM MgCl₂, 1 mM PMSF, containing either 1% Triton X-100 (for Triton extracts) or 1% digitonin (for digitonin extracts), using the FPLC system (Amersham Pharmacia Biotech). FPLC was performed at a flow rate of 0.2 ml/min, and 1-ml fractions were collected. Fractions were analyzed for the presence of Vrg4-HAp by SDS-PAGE, followed by immunoblotting with HA-specific antibodies. For determination of molecular weight, a calibration kit containing proteins that range from 29,000 to 700,000 (Amersham Pharmacia Biotech) was also fractionated by FPLC in parallel and detected by staining with Coomassie Blue. Gas1p, which was also used as a molecular weight marker, was detected by Western blotting using anti-Gas1p polyclonal antibodies.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Vrg4p Fractionates as a Homodimer during Chromatography-- Using co-immunoprecipitation assays of detergent-solubilized, epitope-tagged Vrg4 proteins, coincident with other studies (1) we found that Vrg4p exists as a multimer. To investigate its oligomeric properties, the molecular weight of the Vrg4p-containing complex was examined by gel filtration chromatography. Detergent extracts prepared from yeast expressing an HA-tagged VRG4 allele were fractionated by FPLC over a Superose 6 column. This tagged allele can complement the hygromycin B sensitivity of a vrg4 mutant, indicating that this epitope does not alter the normal function of Vrg4p (8). Protein extracts were prepared under conditions that favored stable Vrg4p-containing oligomeric complexes, assayed by the co-immunoprecipitation of HA- and myc-tagged Vrg4 proteins (e.g. see Fig. 4 and "Experimental Procedures"). Either 1% Triton X-100 or 1% digitonin was used to solubilize proteins, and extracts were fractionated in the same lysis buffer, to maintain stable complexes throughout the procedure. Fractions were analyzed for the presence of Vrg4-HAp by SDS-PAGE, followed by immunoblotting with HA-specific antibodies.

A comparison of the distribution of Vrg4-HAp and molecular weight standards showed that the peak position of Vrg4-HAp elution corresponds to a molecular mass of about 67 kDa (Fig. 1), which is about twice the predicted molecular mass of monomeric Vrg4p. The peak of Vrg4p elution was the same whether the fractionation was performed with buffer containing 1% Triton X-100 or 1% digitonin (Fig. 1). This result suggested that the size of Vrg4p-containing complex is similar in the presence of both 1% Triton and 1% digitonin. The majority of Vrg4-HAp prepared from digitonin extracts was recovered in a sharp, symmetrical peak. No material of a lower molecular weight could be detected, suggesting that most of the Vrg4p extracted from cells by digitonin exists as a homogenous higher molecular weight species. In contrast, when prepared from Triton extracts, Vrg4p was recovered in a broader peak, with a trailing edge of fractions containing monomeric forms of Vrg4 that co-eluted with lower molecular weight standards. This observation is consistent with our results that demonstrated a reduced stability of the Vrg4p-containing complex in Triton X-100 compared with digitonin during co-immunoprecipitation (data not shown).

View larger version (26K): [in this window] [in a new window]   Fig. 1.   Vrg4p exists in a ~65-kDa complex during gel filtration chromatography. Detergent extracts were prepared from a yeast strain (SEY6210) expressing Vrg4-HAp (pRHL-HA3) and fractionated by FPLC over a Superose 6 column (see "Experimental Procedures"). Aliquots of fractions were subjected to SDS-PAGE and Western blotted with anti-HA antibodies. Only peak fractions are indicted.

The predicted molecular mass of the Vrg4p monomer is 36 kDa, and under denaturing gel electrophoresis, it migrates with an apparent molecular mass of about 32 kDa. It is known that the interaction of detergents with some membrane proteins may alter their apparent molecular weight during gel filtration. Therefore we anticipated that the migration profile of Vrg4p-containing complexes would be an indication of the upper limit of the true molecular weight of the complex. Vrg4p elutes with an apparent molecular mass that is about twice that of the monomer. Taken together with co-immunoprecipitation results, these data suggest that Vrg4p exists as a homodimer, although its association with other low molecular weight molecules cannot be ruled out.

Phenotypic Characterization of vrg4 Mutants Encoding Proteins with N- and C-terminal Deletions-- To identify regions of the Vrg4 protein important for function, a series of vrg4 mutant alleles were constructed that encode proteins with deleted termini. Each of these proteins were also epitope tagged at the nondeleted end to facilitate further analyses (see "Experimental Procedures"). Schematic diagrams of these truncated proteins are shown in Fig. 2A. Each vrg4 allele was first assayed for functionality by monitoring complementation of the hygromycin B growth sensitivity of the viable vrg4-2 mutant. While deletion of either the first 15 amino acids or the last 13 amino acids had little effect on protein function, deletion of the N-terminal 44 amino acids (vrg4-44N, which lacks the N-terminal cytosolic tail) or the C-terminal 34 amino acids (vrg4-34C, which lacks the last predicted TMD) impairs protein function. Mutant alleles encoding these truncated proteins completely failed to complement both the drug sensitive phenotype of the vrg4-2 mutant, as well as its glycosylation defect (data not shown).

View larger version (98K): [in this window] [in a new window]   Fig. 2.   Amino acids at the N and C terminus of Vrg4p are required for viability. A, shown is a schematic diagram depicting the HA- and myc-tagged wild type and mutant Vrg4 proteins containing deletions at their termini. Hatched boxes represent the position of predicted transmembrane domains (see Fig. 9 for model). B, strain XGY11, containing VRG4 under control of the glucose repressible GAL1 promoter was transformed with plasmids containing VRG4-HA or a vrg4 alleles (as indicated) and streaked onto YPA medium supplemented with galactose or glucose.

To determine whether vrg4-44N and vrg4-34C are null alleles, complementation of the lethality associated with loss of VRG4 function was examined. Each of these mutant alleles was introduced into a yeast strain containing VRG4 under the control of the glucose-repressible GAL1 promoter. This strain grows normally in the presence of galactose, but fails to grow when VRG4 gene expression is repressed in the presence of glucose. As expected from our examination of glycosylation phenotypes (data not shown), deletion of the first 15 amino acids of Vrg4p had minor effects, since expression of vrg4-15Nsupported the growth of the GAL1-VRG4 strain in the presence of glucose (Fig. 2B). Similarly, vrg4-6C and vrg4-13C also encode proteins that support viability. In contrast, neither vrg4-44N, vrg4-78N, nor vrg4-34C supported the growth of the GAL1-VRG4 strain in the presence of glucose (Fig. 2B), demonstrating that these alleles encode nonfunctional GDP-mannose transporters.

The C Terminus of Vrg4p Is Required for Protein Stability-- To study the role of these mutations on Vrg4 function, we examined their effect on protein stability by Western blot analysis. The steady state level of the mutant Vrg4C proteins that were myc-tagged at the N terminus was quantitatively compared with that of the wild type Vrg4-myc protein, with anti-myc antibody (Fig. 3). While a deletion of 6 or 13 amino acids had no affect on protein stability, a deletion of an additional 21 amino acids (Vrg434Cp) that removes the predicted C-terminal TMD (see Fig. 9) destabilized the Vrg4 protein and resulted in levels 5-10-fold lower than wild type (Fig. 3). As described by Abe et al. (1), we also found that Vrg4 proteins lacking these C-terminal 35 amino acids failed to oligomerize and accumulated in the ER (data not shown). These results demonstrate that sequences predicted to comprise the last TMD in the C terminus of Vrg4p are required for protein stability and suggest that their retention in the ER is simply a result of their instability and failure to assemble.

View larger version (43K): [in this window] [in a new window]   Fig. 3.   Vrg4 proteins containing C-terminal deletions are unstable. Whole cell extracts were prepared from yeast (SEY6210) harboring plasmids that encode myc-tagged Vrg4p protein (YEpGAPVRG4-N-myc3), Vrg4-6Cp (YEpGAP6C-myc3), Vrg4-13Cp (YEpGAP13C-myc3), or Vrg4-34Cp (YEpGAP34C-myc3). Equivalent amounts of protein in each sample was separated by SDS-PAGE and immunoblotted with anti-myc antibody as described under "Experimental Procedures."

Mutant Vrg4 Proteins Containing N-terminal Deletions Are Stable and Retain the Ability to Multimerize-- To determine whether deletion of 44 or 78 amino acids at the N terminus of Vrg4p altered its stability, the steady state levels of these mutant proteins were compared quantitatively to that of the wild type Vrg4 protein. Yeast strains were constructed that co-express wild type VRG4-HA₃ and each of the mutant vrg4N-myc₃ genes or that co-express HA- and myc-tagged mutant vrg4N alleles. Membrane proteins from each of these strains were solubilized with 1% digitonin and analyzed by immunoblotting with anti-myc antibody (Fig. 4, upper panel). By this assay, we found that the levels of the wild type and mutant Vrg4N-myc proteins were virtually indistinguishable (Fig. 4, top panel, compare lanes 1 and 5 with lanes 2, 3, 4, 6, 7, and 8). This was also true of HA-tagged proteins or when these alleles were expressed from a low copy, CEN vector (data not shown). These results demonstrate those Vrg4 proteins containing a deletion of 15, 44, or 78 amino acids are as stable as their wild type counterpart.

View larger version (46K): [in this window] [in a new window]   Fig. 4.   Vrg4 proteins containing N-terminal deletions are stable and maintain the ability to homo-oligomerize. Detergent lysates were prepared from yeast (RSY255) co-expressing HA-tagged and myc-tagged alleles of wild type and/or mutant vrg4 N alleles as described under "Experimental Procedures." Aliquots were analyzed by Western blot (upper panel) using anti-myc antibody, to measure protein stability and by a co-immunoprecipitation assay (lower panel), to compare multimerization properties in which proteins were immunoprecipitated with anti-HA antibodies, fractionated by SDS-PAGE, Western immunoblotted with anti-myc antibodies, and detected by chemiluminescence. In the lower panel, homodimer formation is assayed in lanes 1-4, where strains expressed identical vrg4 alleles that were HA- or myc-tagged, while heterodimer formation was assayed in lanes 5-8, where yeast strains co-expressed a wild type HA-tagged VRG4 gene and a myc-tagged mutant vrg4N allele. The myc-tagged proteins were expressed from plasmids YEplacVRG4-myc3, YEplac15N-myc3, YEplac44N-myc3, and YEplac78N-myc3 transformed into XGY13, a strain that expresses VRG4-HA3 (lanes 5-8) or into RSY255 co-transformed with YEpGAPVRG4-HA3, YEpGAP15N-HA3, YEpGAP44N-HA3, YEpGAP78N-HA3. In lane 9, extracts were prepared from RSY255, transformed with only YEplac78N-myc3, so this strain does not express HA-tagged VRG4.

To determine whether the N-terminal deleted proteins were affected in their oligomer assembly properties, a co-immunoprecipitation assay was used. The same detergent extracts used in the Western blot assay described above were incubated with the anti-HA monoclonal antibody. To measure the relative amount of myc-tagged mutant protein that associated with the HA-tagged mutant or wild type Vrg4 protein, proteins precipitated with anti-HA antibody were fractionated by SDS-PAGE and immunoblotted with anti-myc rabbit antiserum (Fig. 4, lower panel). Vrg4-HAp interacted as well with each of the truncated proteins as it did with itself since comparable amounts of myc-tagged Vrg4p, Vrg415Np, Vrg444Np, and Vrg478Np precipitated with Vrg4-HAp (Fig. 4, lower panel, compare lane 5 with lanes 6-8). This result was also observed when dimer formation was assayed by FPLC, where the majority of Vrg478N-HAp was in a high molecular weight complex that co-eluted with the wild type Vrg4-mycp (data not shown). We routinely observed a slightly increased level of Vrg444N-mycp and Vrg478Np that co-precipitated, compared with Vrg4-myc or Vrg415-myc (Fig. 4, lower panel, compare lanes 1 and 2 to lanes 3 and 4). Although the basis for this increase is not understood, it suggests that these nonfunctional complexes are either more stable or of an altered structure that increases their precipitation by antibody.

The truncated Vrg4N proteins also formed mutant homodimers effieciently. The amount of myc-tagged Vrg415Np, Vrg444N or Vrg478p that "self"-associated was the same as that which precipitated with wild type Vrg4-HAp (Fig. 4, lower panel, compare lanes 2-4 with lanes 6-8), indicating that the formation of mutant homodimers was as efficient as mutant/wild type heterodimers. These results demonstrate that amino acids between 15 and 44 at the N terminus of Vrg4p are essential for viability, but not for protein stability or oligomer assembly.

Overexpression of vrg444N-HA Results in a Dominant Negative Phenotype-- The experiments described above provide strong biochemical evidence that Vrg4p exists as a homodimer, but do not address the question of whether dimer formation is important for its in vivo function. To test this idea, we took advantage of the vrg444N allele, since it encodes a nonfunctional protein that maintains the ability to multimerize. If homodimerization is important for Vrg4p function in vivo, then overexpression of the vrg444N allele should confer a dominant negative growth phenotype, via its ability to bind to and form inactivate dimers with the endogenous wild type Vrg4p. High copy plasmids that overexpress either VRG4, vrg444N, or vrg434C allele were introduced into yeast. Each of these strains was streaked onto selective media supplemented with hygromycin B. Overproduction of Vrg4-34Cp, which fails to multimerize (Ref. 1 and data not shown) or the wild type Vrg4p, had no effect on growth phenotype (Fig. 5). In contrast, overexpression of the vrg444N allele impaired growth on this medium; this strain grew as poorly as the vrg4-2 mutant. (Fig. 5). These genetic data agree well with the co-immunoprecipitation experiments described above (Fig. 4) that demonstrate N-terminal Vrg4 deletion proteins multimerize efficiently and also suggest that dimer formation is essential for GDP-mannose transport to occur in vivo.

View larger version (34K): [in this window] [in a new window]   Fig. 5.   Overproduction of Vrg444N protein confers a dominant negative phenotype. VRG4+ yeast were transformed with high copy plasmids containing HA-tagged VRG4-HA (YEpGAPVRG4-HA3) vrg444N (YEpGAP44N-HA3), vrg434C (YEpGAP34C-myc3) empty vector and plated on SD medium (2% glucose, 0.67% yeast nitrogen base without amino acid) lacking uracil, supplemented with 50 µg/ml hygromycin B. The hygromycin B sensitive strain, NDY5, containing the vrg4-2 mutation was also plated as a control.

Deletion of the N-terminal Domain of Vrg4p Results in Its Mislocalization-- Since the vrg444N and vrg478N alleles encode proteins that are stable and that can assemble into oligomers, this raised the question of what is the biochemical basis for the loss of protein activity. GDP-mannose transport activity is associated with Golgi membranes (7), and the Vrg4-HA protein is localized to the yeast Golgi (8). One possible explanation for its inactivity is that the N terminus of Vrg4p is required for proper Golgi localization. To test whether these mutant Vrg4 proteins are mislocalized, we compared their intracellular location to that of the normal Vrg4 protein. Cells co-expressing VRG4-myc and vrg415N-HA, vrg444N-HA or vrg478N-HA were fixed with formaldehyde, and each protein was detected by indirect immunofluorescence using antibodies directed against the myc or HA epitope. As expected, deletion of the first 15 amino acids had no effect on protein localization; Vrg415N-HAp displayed the same punctate pattern characteristic of the yeast Golgi that was also observed for the wild type Vrg4 protein. In contrast, a deletion of 44 or 78 amino acids resulted in the mislocalization of the mutant proteins to the ER (Fig. 6), and this was the case whether these mutant proteins were overexpressed or expressed at lower copy number (data not shown). The ER mislocalization of Vrg444Np and Vrg478Np is not simply due to high protein expression levels, because both mutant and wild type proteins are found at comparable intracellular levels. Although these mutant proteins were mislocalized to the ER, a significant fraction of both Vrg444Np and Vrg478Np was also observed in punctate spots, suggesting that these proteins are partitioned in both the ER and the Golgi. On the other hand, wild type Vrg4 protein that was co-expressed in these strains was found exclusively in the Golgi (Fig. 6). Two conclusions can be drawn from these results. First, since these mutant proteins can homodimerize (Fig. 4), the localization of mutant proteins in the ER is not due to their failure to assemble into oligomers. Second, since Vrg444N and Vrg478N proteins interact with the wild type Vrg4p (Fig. 4), a proportion of Golgi-localized complexes must be hetero-oligomeric, containing both mutant and wild type subunits. This implies that normal homo-oligomers or mixed hetero-oligomers are competent for ER exit while mutant homo-oligomers are not. These data suggest that amino acids between 16 and 44 are required for export from the ER and that the inactivity of the 44N and 78N mutant Vrg4 proteins may be due, at least in part, to their mislocalization in the ER.

View larger version (92K): [in this window] [in a new window]   Fig. 6.   Deletion of N-terminal sequences between amino acid 15 and 44 cause mislocalization of Vrg4p to the ER. Indirect immunofluorescence was of yeast (SEY6210) co-expressing Vrg4-myc3p and the mutant Vrg4-HA proteins containing N-terminal deletions. Fixed cells, which co-expressed Vrg4-myc3p (YEplac181-RHLmyc3) and each of the mutant N-terminal deleted HA-tagged protein (YEpGAP15N-HA3, YEpGAP44N-HA3, YEpGAP78N-HA3) or wild type Vrg4-HAp (YEpGAPVRG4-HA3), were treated with anti-HA or anti-myc antibodies, followed by fluorescein isothiocyanate-conjugated anti-mouse IgG, as described under "Experimental Procedures."

The N Terminus of VRG4 Can Direct an ER Protein to the Golgi-- The accumulation of misfolded, unstable proteins or unassembled oligomeric proteins in the ER via quality control mechanisms is well documented. This idea can certainly explain the accumulation of Vrg4C proteins in the ER (1) as these mutant proteins appears to be both unstable (Fig. 3) and monomeric (Ref. 1 and data not shown). However, this idea does not satisfactorily account for the mislocalization of Vrg4N44p and Vrg4N78p in the ER, since both the mutant proteins are stable and fully competent to multimerize (Fig. 4).

To examine whether this N-terminal region of the protein may act as an ER export signal, we asked if it could target a resident ER protein to the Golgi. To approach this problem, we took advantage of a highly related Vrg4p homologue, encoded by the HVG1 gene. Although Hvg1p is 88% identical along its length to Vrg4p, it is not functionally redundant and fails to complement a vrg4 mutant even when overexpressed (Ref. 8 and see Fig. 7). A significant difference between Vrg4p and Hvg1p is that Hvg1 is a natural truncated variant of Vrg4p, lacking the N-terminal 98 amino acids that are present in Vrg4p (see alignment in Fig. 7). Although the function of Hvg1p is unknown, analysis of its intracellular localization by indirect immunofluorescence demonstrated that, unlike Vrg4p, Hvg1 resides in the ER and not in the Golgi (Fig. 8). Remarkably, the nucleotide sequences of the 5'-untranslated region (UTR) of HVG1 that correspond to the 5'-translated region of VRG4 have not significantly diverged, except for the presence of an in-frame stop codon (denoted by asterisk in Fig. 7A) upstream the initiating ATG in HVG1 (denoted by the arrow in Fig. 7A) that causes the translation of a shorter protein.

View larger version (53K): [in this window] [in a new window]   Fig. 7.   The 5'-UTR of HVG1 encodes a sequence that is functionally equivalent to the N terminus of Vrg4p. A shows an alignment of Vrg4p and Hvg1p and includes the predicted translation of the 5'-UTR of HVG1. The arrow depicts the initiating methionine of Hvg1p. The asterisk denotes the position of the stop codon found upstream the initiating methionine that was mutated to an arginine codon in mHVG1 (see text). B, Western blot analysis of the Hvg1-HA and mHvg1-HA proteins. Whole cell lysates from 10 OD units of yeast cells (SEY6210) expressing vector alone (lane 1), HA-tagged mHVG1-HA on a 2µ (lane 2) or CEN plasmid (lane 4) or HVG1-HA on a 2µ (lane 3) or CEN plasmid (lane 5) were immunoprecipitated with anti-HA monoclonal antibodies. The entire immunoprecipitate was subjected to SDS-PAGE, Western immunoblotted with anti-HA rabbit antibodies, and detected by chemiluminescence. C, strain NDY5, containing the vrg4-2 mutation, was transformed with 2µ or CEN-containing plasmids encoding mHvg1-HAp or Hvg1p and plated on medium containing 50 µg/ml hygromycin B. Also shown as a control is the growth phenotype of NDY5 (vrg4-2) and its isogenic wild type parental strain, RSY255 (VRG4).

View larger version (55K): [in this window] [in a new window]   Fig. 8.   Addition of the related Vrg4p N terminus on Hvg1p or on Ypl244c41-HA causes their export from the ER to the Golgi. Indirect immunofluorescence of SEY6210 expressing mHVG1-HA or HVG1-HA (A) or Ypl244-HA3, Ypl244N41-HA3, or Vrg4 N47-Ypl244N41-HA3 (B). Fixed cells were treated with anti-HA antibodies, followed by fluorescein isothiocyanate-conjugated anti-mouse.

The 5'-UTR of HVG1 is predicted to encode amino acid sequences nearly identical to those found in the N terminus of Vrg4p. To determine whether this related sequence is sufficient to drive ER export to the Golgi, site-directed mutagenesis was used to change the stop codon normally found in the 5'-UTR of HVG1 to the corresponding arginine codon found at position 78 of the Vrg4 protein. This mutation appends an N terminus on Hvg1p that is 95% identical to that of Vrg4p. Western blot analysis of HA-tagged Hvg1 and the mutated Hvg1-HAp ("mHvg1") containing the additional N-terminal portion demonstrated that both proteins of the correct predicted molecular weight are expressed (Fig. 7B) though at much lower levels than Vrg4-HAp (data not shown). Despite lower expression levels, the additional N terminus represents a gain-of-function mutation. mHVG1 can complement a vrg4 mutant when overexpressed, although not when expressed from a CEN plasmid (Fig. 7C) consistent with our assumption that the additional N-terminal sequence is functionally equivalent to that of Vrg4p.

The intracellular localization of Hvg1-HA and mHvg1-HA was examined by indirect immunofluorescence, using anti-HA antibody. While Hvg1 is found primarily in the ER, mHvg1p, containing the additional N-terminal domain is found exclusively in the Golgi (Fig. 8A). This difference in localization cannot be attributed to differences in expression levels, since both proteins accumulated to comparable levels (Fig. 7B). Similarly, retention of Hvg1 in the ER is not due to its inability to multimerize, since both Hvg1 and mHvg1 can oligomerize (data not shown). Thus, the additional N-terminal domain is sufficient to cause the export of this protein from its normal location in the ER to the Golgi.

We also analyzed the affect of fusing the Vrg4p N terminus onto a less related membrane protein. Ypl244c is a yeast ORF of unknown function that displays homology to the S. pombe UDP-galactose transporter. We found that this protein is primarily localized in the yeast Golgi, although when overexpressed it can also be seen in the ER (Fig. 8B, Ypl244-HAp). Removal of the N-terminal 41 amino acids of Ypl244cp causes its mislocalization to the ER (Fig. 8B, Ypl24441N-HA_p). However, when the N-terminal 47 amino acids of Vrg4p are fused to this truncated Ypl244c protein, this protein is again found primarily in the Golgi complex, although some ER staining is also observed (Fig. 8B, V_N47-Ypl24441N-HA_p). These results suggest that sequences in the N terminus of Vrg4p can supply the information that promotes the ER export of this protein, which is normally found within its N terminus.

The N and C Termini of Vrg4p Face the Cytosol-- The use of secondary structure algorithms and hydropathy analyses predict that Vrg4p contains between six and eight TMDs. To obtain more information about the function of the N and C termini and as a first step toward examining the membrane topology of the Vrg4 protein, it was of interest to examine whether these regions of the protein face the lumen of the Golgi or the cytosol. To do this we used a protease protection assay of epitope tags placed at the C or N termini of Vrg4p. A 7-amino acid recognition site for cleavage by the TEV protease (26) was inserted at the junction of either an N-terminal triple HA tag or a C-terminal protein A tag (Fig. 9A). This TEV recognition sequence is not found in any predicted yeast ORF, so cleavage of these fusion proteins by TEV protease is highly specific. Yeast strains were constructed in which the chromosomal allele of VRG4 was replaced by the N- or C-terminally tagged alleles. These strains, whose sole source of Vrg4p is from the tagged VRG4 alleles, display no growth or glycosylation defect (data not shown), suggesting that neither the N- nor the C-terminal tag affects normal Vrg4 protein folding.

View larger version (29K): [in this window] [in a new window]   Fig. 9.   The N and C termini of Vrg4p face the cytosol. A shows a schematic diagram of the Vrg4 and Gda1 epitope-tagged proteins containing TEV protease cleavage sites (depicted by an arrow) at the N or C terminus that were used for the protease protection assay shown in B, the hatched boxes represent predicted membrane-spanning domains. B, microsomes were prepared from yeast strains containing Vrg4p with an N-terminal TEV tag (XGY11), Vrg4p with a C-terminal TEV tag (XGY10), or Gda1p with a C-terminal TEV tag (XGY12), as described under "Experimental Procedures," and treated with 20 units of TEV protease in the absence () or presence (+) of Triton X-100 or zinc sulfate. Proteins were separated by SDS-PAGE and analyzed by Western immunoblotting followed by chemiluminescence, using anti-HA antibodies or rabbit IgG for the detection of the protein A epitope. C depicts a model for the membrane topology of Vrg4 that combines the results from the protease protection assay, which experimentally place the C and N termini in the cytosol and hydropathy analysis, which predicts six to eight membrane-spanning segments.

To determine whether these epitopes were accessible to digestion by the TEV protease, membrane fractions were prepared from yeast strains expressing these tagged alleles and subjected to digestion with the TEV protease. After digestion, proteins were separated by SDS-PAGE and immunoblotted with antibodies against the HA or protein A tag. Both the N and C termini were digested in the presence of TEV protease (Fig. 9B). Since a C-terminal tag of a control protein, Gda1p, that resides in the lumen (27, 28) was protected from TEV cleavage, the digestion of the N and C termini of Vrg4p was not merely the result of leaky or inverted vesicles (Fig. 9B). Both Vrg4p and Gda1p were digested by TEV protease in the presence of Triton X-100, further demonstrating that the proteolytic protection of Gda1p was specifically due to its lumenal orientation. Neither Gda1p nor Vrg4p was digested when an inhibitor of the TEV protease, ZnS0₄, was included in the incubation, demonstrating the specificity of TEV cleavage. These results demonstrate that both the N and C termini of Vrg4p face the cytoplasm and that this protein contains an even number of membrane spanning domains (see model in Fig. 9C).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Although nucleotide sugar transport activity was first described over twenty years ago, little is known about the molecular mechanisms that drive these reactions. We examined epitope-tagged alleles of VRG4 to study the properties of Vrg4p that relate to its ability to catalyze GDP-mannose transport into the Golgi. The experiments described here establish that this transporter normally functions as a multimer, probably as a homodimer. In addition, through our analyses of mutant alleles, we identified an essential domain that is required for ER export and Golgi localization but that is distinct from another domain required for protein stability and oligomer assembly.

An important result presented in this work is that the Vrg4 protein can interact with itself with high affinity and specificity. Moreover, the predicted molecular weight of the Vrg4p complex, in both Triton X-100 and digitonin, is twice the molecular weight of the monomer, suggesting that Vrg4p functions independently as a homodimer. We looked for evidence of its interaction with other proteins and found none. Vrg4p does not associate with either Gda1p or Ynd1p (data not shown), although an interaction with either of these proteins would not have been surprising, since they are the Golgi GDPases that generate the GMP that perpetuates the nucleotide sugar transport cycle (29, 30). These results are in agreement with radiation inactivation studies that suggest Gda1p is homodimer (27). It therefore appears that the lumenal transport of GDP-mannose, like the hydrolysis of GDP to GMP, is catalyzed by a homodimer that does not require an association with other membrane proteins for function.

With the exception of the Leishmania GDP-mannose transporter, which exists as a hexameric complex (31), recent reports indicate that other nucleotide sugar transporters including the human GDP-fucose (32) and UDP-GalNAc transporter (33) exist as homodimers. The murine CMP-sialic acid transporter, the Kluyveromyces lactis UDP-N-acetylglucosamine transporter, and the human UDP-galactose transporter contain leucine zipper motifs that have been postulated to function in oligomerization though the physical properties of these proteins have not yet been investigated (29, 34, 35). Therefore, dimerization or some higher order structure may be a general feature of nucleotide sugar transporters. Dimer formation of the yeast GDP-mannose transporter is clearly essential for its function in vivo, since inhibition of functional Vrg4p dimer formation in vivo, which we induced experimentally through the overexpression of the vrg444N allele, leads to growth defects.

How might dimer formation contribute to the transport of nucleotide sugars? Some clues may come from studies of the major facilitator superfamily of transporters, whose members are characterized by two structural units of six or seven TMDs, connected by a loop (see Ref. 36 for review). The current view is that this 2-fold symmetry enables the formation of a transmembrane channel through which solutes may pass. The presence of shared sequence motifs in the C- and N-terminal halves of these 12 TMD-containing proteins has led to the hypothesis that these transporters originally arose by a tandem intragenic duplication from primordial six TMD-containing protein (37). A computer analysis of all members of the major facilitator superfamily encoded by the S. cerevisiae genome identified 149 proteins, which include Vrg4p (38, 39). This is despite the fact that Vrg4p is predicted to contain only six to eight TMDs. The idea that Vrg4p exists as a dimer reconciles its anomalous inclusion in this family of transporters that are otherwise are characterized by their conserved topology. Protein dimerization may facilitate the formation of a transmembrane channel that normally requires the packing of 12-14 TMDs.

In the case of the yeast GDP-mannose transporter, Abe et al. (1) recently demonstrated that the C terminus of Vrg4p is required for oligomerization. Mutant vrg4C alleles encoding proteins lacking the last 12, 35, and 62 amino acids failed to complement the glycosylation defect of a vig4 (vrg4) mutant, and residues between the last 12 and 62 amino acids (predicted to encode the last TMD) are required for oligomer formation and are mislocalized in the ER (1). On the basis of these data, they suggest that these sequences may be involved in trafficking Vrg4p from the ER to the Golgi. We obtained similar results, but with some important differences. First, deletions of up to 13 amino acids at the C terminus had little effect on Vrg4p function. Second, and perhaps most importantly, while amino acids predicted to comprise the C-terminal TMD are required for oligomer formation, we found that these amino acids are also essential for protein stability. Proteins lacking this C-terminal TMD are nonfunctional, unstable, and accumulate in the ER, consistent with the idea that quality control mechanisms restrict the exit of these unassembled Vrg4 monomers from the ER and result in their degradation.

We found that the N-terminal cytosolic tail is required for ER export. Unlike the C terminus, deletion of this N-terminal region of the protein, between amino acids 15 and 44, does not affect protein stability or oligomer assembly. The demonstration that Vrg444N proteins efficiently homodimerize with themselves suggests that their retention in the ER is not due to their failure to oligomerize in the ER. Three additional pieces of indirect evidence suggest that these sequences facilitate ER export. First, the Vrg4-related Hvg1 protein lacks this N-terminal sequence and normally resides in the ER. Second, the addition of a highly related N-terminal sequence onto Hvg1p results in its transport to the Golgi. Third, fusion of the Vrg4p N terminus to a truncated UDP-galactose homologue, Ypl244c, restores its localization to the Golgi.

Several possible mechanisms by which the N-terminal tail influences ER export can be envisioned. The first is that it may act as a cytoplasmic cargo recognition signal for the inclusion of Vrg4p into transport vesicles. Alternatively, the N terminus may assist a particular folding conformation that effects the kinetics of export from the ER. The transport of cargo between the ER and the Golgi is mediated by COPII-coated vesicles and requires the sorting and concentration of cargo into these vesicles (see Ref. 40 for review). Cargo selection may involve specialized accessory factors dedicated to a subset of cargo. Several yeast proteins, including Shr3p (41, 42), Gsf2p (43), Erv14p (44), and Lst1p (45), have been described recently that are candidates for these ancillary proteins that facilitate ER export of specific proteins in yeast. With the exception of Lst1p, a relative of the COPII protein, Sec24p (45), whether these other proteins are directly involved in cargo selection is not known. They may simply influence some aspect of protein maturation that is required for the efficient trafficking. Since overexpression of VRG4 does not lead to any obvious secretion defects (data not shown), it seems unlikely that the N terminus interacts directly with the general COPII machinery. Further experiments will be required to distinguish whether this N-terminal tail plays a direct role in sorting via its interaction with some adapter or an indirect role via its influence on protein folding. In conclusion, our results have defined two structural domains of the yeast Golgi GDP-mannose transporter that are critical for its function. The essentiality of this protein underscores the significance of glycosylation in the Golgi.

	ACKNOWLEDGEMENTS

We thank Jay Poster for technical assistance and Akiko Nishikawa for help in DNA sequencing.

	FOOTNOTES

^* This work was supported by Grant GM48467 from the National Institutes of Health (to N. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 631-632-9309; Fax: 631-632-8575; E-mail: ndean@notes.cc.sunysb.edu.

Published, JBC Papers in Press, March 27, 2000, DOI 10.1074/jbc.M909946199

² (1996) Poster 110 presented at the , , ().

	ABBREVIATIONS

The abbreviations used are: NST(s), nucleotide sugar transporter(s); TEV, tobacco etch virus; PCR, polymerase chain reaction; ORF, open reading frame; HA, hemagglutinin; PMSF, phenylmethylsulfonyl fluoride; FPLC, fast protein liquid chromatography; PAGE, polyacrylamide gel electrophoresis; ER, endoplasmic reticulum; UTR, untranslated region; TMD(s), transmembrane domain(s).

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES